Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

UNC1215

Copy Product Info
🥰Excellent
Catalog No. T2379Cas No. 1415800-43-9

UNC1215, an effective and specific MBT (malignant brain tumor) antagonist, binds L3MBTL3 (IC50/Kd: 40/120 nM). The selectivity of UNC1215 for L3MBTL3 is 50-fold higher versus other members of the human MBT family.

UNC1215

UNC1215

Copy Product Info
🥰Excellent
Purity: 99.04%
Catalog No. T2379Cas No. 1415800-43-9
UNC1215, an effective and specific MBT (malignant brain tumor) antagonist, binds L3MBTL3 (IC50/Kd: 40/120 nM). The selectivity of UNC1215 for L3MBTL3 is 50-fold higher versus other members of the human MBT family.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
2 mg$35In StockIn Stock
5 mg$56In StockIn Stock
10 mg$98In StockIn Stock
25 mg$197In StockIn Stock
50 mg$355In StockIn Stock
100 mg$526In StockIn Stock
1 mL x 10 mM (in DMSO)$66In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.04%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
UNC1215, an effective and specific MBT (malignant brain tumor) antagonist, binds L3MBTL3 (IC50/Kd: 40/120 nM). The selectivity of UNC1215 for L3MBTL3 is 50-fold higher versus other members of the human MBT family.
Targets&IC50
L3MBTL3:120 nM(Kd), L3MBTL3:40 nM
In vivo
UNC1215 binds to L3MBTL3 and competitively displaces peptides containing mono- or dimethyl-lysine.UNC1215 is approximately 75-fold more selective for L3MBTL3 than L3MBTL1.UNC1215 is non-cytotoxic and binds directly to L3MBTL3 through the Kme-binding pocket of the MBT domain.UNC1215 enables the cellular mobility of GFP-L3MBTL3 fusion proteins and the cellular mobility of the fusion protein. UNC1215 increased cell mobility and point mutations of the GFP-L3MBTL3 fusion protein, interfered with the Kme-binding function of the GFP-L3MBTL3 phenotypic mimic, and affected the localization of UNC1215.UNC1215 (30 μM) did not affect the tandem Tudor domain of UHRF1, the chromatin domain of CBX7, and the PHD domain of JARID1A.
Kinase Assay
AlphaScreen assay: Compound plates (1 μL at 10 or 30 mM highest concentration) are diluted in 1×assay buffer (20 mM Tris pH 8.0, 25 mM NaCl, 2 mM DTT and 0.05% Tween-20) over 2 steps using a Multimek robotic pipettor and 1 μL is spotted into the wells of 384-well assay Proxiplates. To these plates 9 μL of protein- peptide mix in 1× assay buffer is added by Multidrop and incubated for 30 min at room temperature. At this point 2 μL of streptavidin-conjugate donor and nickel-chelate acceptor beads (45 μg/mL in 1× assay buffer) are added, the plates are allowed to incubate for an additional 30 min in the dark at room temperature. After incubation the plates are read on EnVision mulilabel reader equipped with HTS alpha screen laser. The screens reported are performed up to 10 or 30 μM, and therefore it should be noted that those compounds referred to as inactive are indeed inactive only within the concentration range tested. PHF23 and JARID1A are GST tagged and consequently for these assays GST-acceptor beads are used. It should be noted that any positive binding curves for L3MBTL4 that are generated yielded curves with very shallow slopes, suggesting a nonspecific interaction. The data for the IC50 values is calculated from replicate runs in that the datapoints for each compound concentration are averaged and plotted using 4-parameters curve fitting.
Cell Research
CellTiter-Glo luminescent cell viability assay(Only for Reference)
Chemical Properties
Molecular Weight529.72
FormulaC32H43N5O2
Cas No.1415800-43-9
SmilesO=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1
Relative Density.1.224 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 93 mg/mL (175.56 mM), Sonication is recommended.
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 93 mg/mL (175.56 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (1.89 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
1 mM1.8878 mL9.4389 mL18.8779 mL94.3895 mL
5 mM0.3776 mL1.8878 mL3.7756 mL18.8779 mL
10 mM0.1888 mL0.9439 mL1.8878 mL9.4389 mL
20 mM0.0944 mL0.4719 mL0.9439 mL4.7195 mL
50 mM0.0378 mL0.1888 mL0.3776 mL1.8878 mL
100 mM0.0189 mL0.0944 mL0.1888 mL0.9439 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy UNC1215 | purchase UNC1215 | UNC1215 cost | order UNC1215 | UNC1215 chemical structure | UNC1215 in vivo | UNC1215 formula | UNC1215 molecular weight